



Examples of screen shots of economic models developed by OUTCOMES INTERNATIONAL
(note that some screen contents are neutralized for confidentiality reasons)

1.1. Cover screens



1.2. Navigation screens

Economic Value of Treatment A versus Treatment B in the Management of Patients with Macular Degeneration

A cost-minimization analysis

Please click on the desired button

Language / Sprache

English
 German

Resource Use Input Data

Economic Input Data

Clinical Outcomes

Economic Outcomes

Graphs

Information / Background

Literature Synthesis

Exit

Print

Funded by a grant from:

Model development and copyright (model software):
OUTCOMES INTERNATIONAL
CH- 4052 Basel

Version V3: March 5, 2005

1.3. Data input screens

Economic Model Simulation - [Basic Data]

File Results Options Parameters Help

Basic Data Inputs for Simulation

First select an Indication, then an appropriate Parameter Set. Select a Reference treatment from the list. Edit the parameters to the right as necessary and then press the Continue.. button.

Indication: Reference treatment:

Number of procedures: 100%

Country/Currency:

Parameter set:

Active parameter set of file

ID	Title	Indication	DF
1	Parameter Set for Ostial renal stenosis	Ostial renal stenosis	-1

Treatment distribution (%):

Medical:	<input type="text" value="20"/> %	800
PTA:	<input type="text" value="20"/> %	800
Stent:	<input type="text" value="30"/> %	1200
Surgery:	<input type="text" value="30"/> %	1200

Discount rate (%):

EXIT

Cost-Effectiveness of Universal Vaccination of Infants Against Gastrointestinal Infection

VARIABLE	VALUE	SOURCE / COMMENT
General Information		
Country	France	
Currency	€	
Economic perspective	Societal	
Time frame of analysis (years)	5	
Date of analysis	25.04.2006	
Name of analysis		
Demography		
Birth cohort (N)	772'000	UNICEF's State of the World's Children Report 2004 (data from 2002)
Natural mortality		
Cumulative natural survival rate at age 1 year	0.99576	INED data
Cumulative natural survival rate at age 2 years	0.99542	
Cumulative natural survival rate at age 3 years	0.99518	
Cumulative natural survival rate at age 4 years	0.99499	

Economic Varicella Vaccination Tool for Analysis - Standard Parameters

File Parameters Help

Main Page
Product Description
Decision Model
References
General Parameters
Clinical Parameters
Economic Parameters
Run Simulation
Exit

Basic Outpatient Complications Inpatient Disability

Coverage

Start	<input type="text" value="30"/> %
End	<input type="text" value="85"/> %
Years	<input type="text" value="5"/>
Catch-Up	<input type="text" value="30"/> %

Infectious Force

0 - 4 years	<input type="text" value="0.110000"/>
5 - 9 years	<input type="text" value="0.205000"/>
10 - 14 years	<input type="text" value="0.170000"/>
15 - 19 years	<input type="text" value="0.090000"/>
>= 20 years	<input type="text" value="0.060000"/>

Vaccine Efficacy Parameters

Vaccine Efficacy	<input type="text" value="86"/> %
Waning Rate	<input type="text" value="0.5"/> %
Relative Suscept.	<input type="text" value="12"/> %
Relative Infect.	<input type="text" value="40"/> %
Relative Probabil. Major Complications	<input type="text" value="1"/> %
Vaccine Complication Rate	<input type="text" value="2"/> %

Boosting Rate

Susceptible	<input type="text" value="0"/> %
Protected	<input type="text" value="0"/> %

Model Input Data

General Data

Name of clinic:

Name of dataset:

Date of analysis: 03.02.2006

Country: Belgium

Currency: EUR

Total number of CABG procedures per year: 100

Percentage of endoscopic vessel harvesting (EVH) procedures: 50%

Conversion rate (EVH -> OVH): 1.0%

Clinical Input Data

	EVH	OVH
<i>Postoperative wound complications</i>		
Dehiscence	0.0%	0.6%
Cellulitis	0.8%	0.0%
Major neuralgia	1.0%	8.0%

CRT Model

File Edit Information

Data Set

Best case analysis new - Germany

Select Data Set

Input

Basic Input Data

Demographic Input Data

Clinical Input Data

NYHA / Utility Input Data

Economic Input Data

Output

Run Simulation

Animated Simulation

Key Results

Data Export To Excel

Information

Introduction

Model Description

Literature

Input Data - Overview

Quality of life with OPT alone | Quality of life following CRT implantation

Distribution of patient population at:

	Baseline	M0-6	M0-12	Utility value
NYHA class IV	10.0	5.0	5.0	0.30
NYHA class III	90.0	20.0	20.0	0.65
NYHA class II	0.0	55.0	55.0	0.80
NYHA class I	0.0	20.0	20.0	0.97
Average NYHA class of survivors	3.1	2.1	2.1	
Average utility value	0.6	0.8	0.8	

Reset Save

Economic Varicella Vaccination Tool for Analysis - Standard Parameters

File Parameters Help

Main Page

Product Description

Decision Model

References

General Parameters

Clinical Parameters

Economic Parameters

Run Simulation

Exit

Vaccination Treatment **Outpatient** Inpatient Work Loss

Outpatient treatment costs related to infection complications (in DEM)

Child	No. Visits	Diagnostics	Treatment	Other
Bact. superinfection + scarring	2.0	0.00	90.00	0.00
Pneumonia + bronchitis	2.0	16.80	29.00	0.00
Acute neurological disorder	1.0	11.90	29.00	0.00
Otitis media	2.0	7.00	26.00	0.00
Other complication	1.0	0.00	0.00	0.00

Adult	No. Visits	Diagnostics	Treatment	Other
Bact. superinfection + scarring	1.5	0.00	116.00	0.00
Pneumonia + bronchitis	3.0	16.80	59.00	0.00
Acute neurological disorder	1.5	11.90	59.00	0.00
Otitis media	2.0	7.00	36.00	0.00
Other complication	1.0	0.00	0.00	0.00

1.4. Model results screens


Navigation Screen Model Input Data Model Diagram **Clinical Outcomes** Economic Outcomes Graphs

Clinical Outcomes (Intention-to-treat)
Analysis per treatment group

Variable	Vessel harvesting procedure		Abs. difference EVH vs. OVH
	EVH	OVH	
Number of cases	125	125	
Number of conversions (EVH -> OVH)	1		1
Number of post-operative wound complications *			
Dehiscence	0	1	-1
Cellulitis	1	0	1
Major neuralgia	1	10	-9
Forearm ischemia	0	0	0
Hematoma	3	6	-4
Arm wound infection	0	3	2
Hospital readmission			
Other wound comp			
Other wound comp			


Save
Exit
Home




Health outcomes	Strategy		Cases prevented by vaccination
	No vaccination	Vaccination	
* Note: a patient can have more than one complication			
Discount rate health benefits (%):	0		
Time frame of analysis (years):	30		
Cases with infection	22,169,023	3,812,943	18,356,080
Total complications (any severity)	1,191,663	204,480	987,183
<i>Bacterial superinfection / scarring</i>	534,606	91,283	443,323
<i>Pneumonia / bronchitis</i>	224,225	38,842	185,383
<i>Acute neurological disorder</i>	30,281	5,116	25,165
<i>Otitis media</i>	189,257	31,973	157,284
<i>Other complication</i>	213,294	37,266	176,028
Major complications requiring hospitalization	172,162	29,953	142,209
		1,721	8,479
		21,250	99,355
		2,245	11,049
		0	0
		4,737	23,326
		0	0
		117	554



Economic Outcomes			
Analysis per patient			
Variable	Vessel harvesting procedure		EVH vs. OVH
	EVH	OVH	
	Cost (EUR)	Cost (EUR)	
Total cost	4'205	4'188	17
Vessel harvesting procedure	422	133	289
<i>Medical personnel</i>	22	17	4
Surgeon	22	17	4
Nurse	0	0	0
<i>Materials</i>	401	116	285
Endovascular Tool Kit	300	0	300
Depreciation cost of technical equipment	17	0	17
Suture material	4	16	-12
Other disposable materials (e.g. bandages, drugs)	80	100	-20
Postoperative wound complications	9	13	-4
Dehiscence	0	4	-4
Cellulitis	6	0	6
Major neuralgia	0	0	0
Forearm ischemia	0	0	0
Hematoma	4	9	-5
Arm wound infection	0	0	0
Hospital readmission	0	0	0
Other	0	0	0
Other	0	0	0

Cost of hos	Cost components	Strategy		Difference vaccination vs. no vaccination
		No vaccination	Vaccination	
Follow-up p	Currency: 'Euro'			
	Discount rate costs (%): 5			
	Discount rate health benefits (%): 0			
	Time frame of analysis (years): 30			
	Direct medical costs	530,549,448	948,583,073	418,033,625
	Total vaccination costs	0	796,463,540	796,463,540
	<i>Vaccine costs</i>	0	715,783,679	715,783,679
	<i>Vaccine administration costs</i>	0	80,186,409	80,186,409
	<i>Vaccine complication costs</i>	0	493,454	493,454
	Varicella disease costs	530,549,448	152,119,533	-378,429,915
	Work loss costs covered by health insurancy	575,148,110	160,110,327	-415,037,783
	Total costs	1,105,697,558	1,108,693,400	
	Net costs or savings of mass vaccination			2,995,842





1.5. Model diagram screens (updates automatically in dependence of incorporated input data)

